Histogen  logo
Histogen HSTO
report update icon

Quarterly report 2023-Q3
added 05-16-2026

Histogen Balance Sheet 2022-2005 | HSTO

Brief overview of Histogen 's financial position

The comparison uses five available annual reports from the 2018–2022 interval.

Assets finished at $19.1 million versus $48.8 million initially, losing -60.9%. The balance sheet contracted.

Liabilities grew more slowly than assets: -73.4% versus -60.9%. Expansion relied more on equity, improving funding quality.

The equity-to-assets ratio is 75.5%, compared with 56.1% five periods ago. The balance sheet has a substantial internal cushion.

Cash exceeds interest-bearing debt, producing net debt of -$11.9 million. The balance sheet therefore carries a net cash position.

The cash reserve occupies 63.5% of the balance sheet, previously 23.7%. It is one marker of short-term resilience.

The balance sheet includes a negative accumulated result of -$88.3 million. It should be assessed alongside historical profits and capital distributions.

Balance sheet takeaway

Histogen shows a high-quality balance sheet profile, with adequate internal capital and room for maneuver.

Annual Balance Sheet Histogen

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005

Net Debt

-11.9 M -18.5 M -6.37 M -1.93 M -11.6 M -2.92 M -57.1 M -12.9 M -8.91 M -3.16 M - - - - - - - -

Long Term Debt

5 K 14 K 369 K 31 K - 13.2 M - 1 M 1 M 1 M - - - - - - - -

Long Term Debt Current

238 K 127 K 28 K 108 K - - - - - - - - - - - - - -

Total Non Current Liabilities

- - 5.32 M - 2.88 M 25.8 M 21 M 1.2 M 1.06 M 1 M - - - - - - - -

Total Current Liabilities

1.23 M 2.33 M 2.78 M 1.38 M 18.5 M 28.1 M 39.6 M 3.98 M 4.18 M 2.82 M 1.41 M - - - - - - -

Total Liabilities

5.7 M 7.06 M 8.1 M 1.84 M 21.4 M 53.9 M 60.5 M 5.19 M 5.23 M 3.82 M - - - - - - - -

Deferred Revenue

19 K 19 K 48 K 19 K 10.1 M 14.2 M 30.9 M - - - - - - - - - - -

Retained Earnings

-88.3 M -77.7 M -62.7 M -43.9 M -187 M -168 M -151 M -121 M -96.8 M -74.4 M - - - - - - - -

Total Assets

19.1 M 27.2 M 15 M 2.94 M 48.8 M 81.9 M 82.3 M 39.7 M 38.4 M 56.9 M 8.15 M - - - - - - -

Cash and Cash Equivalents

12.1 M 18.7 M 6.76 M 2.06 M 11.6 M 16.1 M 58.1 M 13.9 M 9.91 M 4.16 M 4.04 M 3.07 M 2.73 M - - - - -

Book Value

13.4 M 20.2 M 6.91 M 1.1 M 27.4 M 28 M 21.8 M 34.5 M 33.2 M 53.1 M 8.15 M - - - - - - -

Total Shareholders Equity

14.4 M 21.2 M 7.86 M -37.1 M 27.4 M 28 M 21.8 M 34.5 M 33.2 M 53.1 M -58.3 M -49.7 M -37.9 M -27.2 M -20.3 M -13.5 M -3.34 M -85.4 K

All numbers in USD currency

Quarterly Balance Sheet Histogen

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

5 K 5 K 3 K 5 K 8 K 9 K 11 K 14 K 369 K 369 K 310 K 369 K 428 K 467 K 369 K 31 K 31 K 116 K 229 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

1.41 M 5.28 M 5.73 M 5.7 M 5.93 M 5.74 M 7.54 M 7.06 M 7.29 M 6.84 M 7.18 M 8.1 M 7.44 M 9.46 M 8.1 M 1.84 M 1.84 M 1.84 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

19 K 19 K 19 K 19 K 19 K 19 K 19 K 19 K 19 K 19 K 19 K 48 K 103 K 157 K 48 K 19 K 404 K 2.13 M 8.15 M 10.1 M 12.7 M 14.4 M 14.9 M 14.2 M 19.5 M 24.6 M 27.4 M 30.9 M 30.9 M 30.9 M 30.9 M - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-97.7 M -93.8 M -91.7 M -88.3 M -85.3 M -81.7 M -78.3 M -77.7 M -74.5 M -70.7 M -67 M -62.7 M -59.2 M -55.9 M -201 M -43.9 M -195 M -192 M -191 M -187 M -183 M -178 M -174 M -168 M -164 M -160 M -154 M -151 M -142 M -135 M -128 M -121 M -115 M -109 M -103 M -96.8 M -91.4 M -85 M -96.8 M -74.4 M -74.4 M 53.9 M - - - - - - - - -

Total Assets

5.82 M 13.5 M 16.1 M 19.1 M 22.2 M 21 M 31.5 M 27.2 M 27.6 M 30.8 M 28.8 M 15 M 14 M 17.8 M 18.8 M 2.94 M 26.2 M 36.2 M 42.2 M 48.8 M 58.1 M 66.9 M 76.6 M 81.9 M 89.3 M 99 M 83.6 M 82.3 M 33.4 M 32.3 M 35.6 M 39.7 M 44.6 M 49.2 M 32.3 M 38.4 M 43.2 M 47.8 M 51.9 M 56.9 M 60.2 M 5.26 M 56.9 M 8.15 M 8.15 M 8.15 M - - - - -

Cash and Cash Equivalents

4.57 M 7.26 M 9.66 M 12.1 M 14.6 M 12.6 M 17.8 M 18.7 M 19.2 M 23.1 M 21.7 M 6.76 M 6.65 M 10.4 M 18 M 2.06 M 18.3 M 13.4 M 19.2 M 11.6 M 13.3 M 11.6 M 16.6 M 16.1 M 14.4 M 15.8 M 16.5 M 58.1 M 14.3 M 13.5 M 19.6 M 13.9 M 14.6 M 8.93 M 8.3 M 9.91 M 11.3 M 8.4 M 2.49 M 4.16 M 35.1 M 3.28 M 4.16 M 4.04 M 4.04 M 4.04 M - 3.07 M - - -

Book Value

4.4 M 8.26 M 10.3 M 13.4 M 16.3 M 15.3 M 24 M 20.2 M 20.3 M 24 M 21.6 M 6.91 M 6.51 M 8.31 M 10.7 M 1.1 M 24.3 M 34.3 M 42.2 M 48.8 M 58.1 M 66.9 M 76.6 M 81.9 M 89.3 M 99 M 83.6 M 82.3 M 33.4 M 32.3 M 35.6 M 39.7 M 44.6 M 49.2 M 32.3 M 38.4 M 43.2 M 47.8 M 51.9 M 56.9 M 60.2 M 5.26 M 56.9 M 8.15 M 8.15 M 8.15 M - - - - -

Total Shareholders Equity

5.44 M 9.29 M 11.4 M 14.4 M 17.3 M 16.3 M 20.7 M 21.2 M 21.3 M 24.9 M 22.6 M 7.86 M 7.44 M 9.23 M 17.6 M -37.1 M 22 M 24.1 M 23.6 M 27.4 M 16.6 M 20 M 23.4 M 28 M 31.3 M 34.3 M 19.5 M 21.8 M 28.2 M 27.8 M 31.4 M 34.5 M 39.8 M 44.4 M 28.1 M 33.2 M 37.8 M 43.5 M 48.3 M 53.1 M 58.1 M -53.9 M 53.1 M -58.3 M -58.3 M -58.3 M - -49.7 M - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Histogen , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.6 5.56 % $ 6.41 B israelIsrael
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 64.67 0.11 % $ 12.4 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
C4 Therapeutics C4 Therapeutics
CCCC
$ 3.85 0.12 % $ 319 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.78 1.13 % $ 3.03 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 34.07 0.17 % $ 382 M usaUSA
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 5.6 2.06 % $ 3.74 M usaUSA
Codexis Codexis
CDXS
$ 1.59 0.3 % $ 139 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.1 1.25 % $ 303 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 199.02 0.31 % $ 9.9 B usaUSA
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 56.28 0.1 % $ 1.62 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Aytu BioScience Aytu BioScience
AYTU
$ 2.25 0.45 % $ 14.1 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada